Virtu Financial’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-434
Closed -$38K – 2212
2022
Q4
$38K Buy
+434
New +$78.7K 0.01% 1134
2022
Q2
– Sell
-52
Closed -$28K – 2186
2022
Q1
$28K Buy
+52
New +$38.9K ﹤0.01% 1252
2021
Q3
– Sell
-23
Closed -$66K – 2063
2021
Q2
$66K Buy
+23
New +$114K 0.01% 1286
2021
Q1
– Sell
-16
Closed -$104K – 2119
2020
Q4
$104K Buy
+16
New +$83.9K 0.01% 1045
2018
Q1
– Sell
-14
Closed -$58K – 2739
2017
Q4
$58K Buy
+14
New +$71.4K ﹤0.01% 2051

Other funds holding ATXI

Virtu Financial's ATXI Position: Q1 2023 in Review

Virtu Financial sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2023, closing a stake of 434 shares — an estimated $38K sold.

Virtu Financial first reported a position in ATXI in Q4 2017 and held it in 5 quarters. The position peaked at $104K in Q4 2020. 13 funds tracked by Wall St. Rank hold ATXI as of Q1 2023.

  • Virtu Financial reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Virtu Financial sold 434 Avenue Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $38K.
  • Virtu Financial first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2017 and held it in 5 quarters.
  • Virtu Financial's Avenue Therapeutics, Inc. Common Stock position peaked at $104K in Q4 2020.
  • 13 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Virtu Financial's 13F filing for Q1 2023, filed 1 May 2023.